According to Insmed's latest financial reports the company's current revenue (TTM) is $0.30 B. In 2022 the company made a revenue of $0.24 B an increase over the years 2021 revenue that were of $0.18 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.30 B | 24.39% |
2022 | $0.24 B | 30.19% |
2021 | $0.18 B | 14.63% |
2020 | $0.16 B | 20.48% |
2019 | $0.13 B | 1287.56% |
2018 | $9.83 M | |
2017 | N/A | |
2016 | N/A | |
2015 | N/A | |
2014 | N/A | -100% |
2013 | $11.5 M | |
2012 | N/A | -100% |
2011 | $4.41 M | -36.18% |
2010 | $6.92 M | -33.28% |
2009 | $10.37 M | -12.8% |
2008 | $11.89 M | 59.17% |
2007 | $7.47 M | 653.33% |
2006 | $0.99 M | 657.25% |
2005 | $0.13 M | -4.38% |
2004 | $0.13 M | -8.67% |
2003 | $0.15 M | -92.33% |
2002 | $1.95 M | 560.47% |
2001 | $0.29 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Novartis NVS | $51.01 B | 16,613.85% | ๐จ๐ญ Switzerland |
Gilead Sciences GILD | $27.11 B | 8,784.11% | ๐บ๐ธ USA |
Vertex Pharmaceuticals VRTX | $9.86 B | 3,133.60% | ๐บ๐ธ USA |
Sarepta Therapeutics
SRPT | $1.24 B | 307.37% | ๐บ๐ธ USA |
Aerie Pharmaceuticals AERI | $0.21 B | -29.90% | ๐บ๐ธ USA |
Array Technologies ARRY | $1.57 B | 416.55% | ๐บ๐ธ USA |